Abbott's Humira gets expanded indication
14th Nov 2006, 18:19 GMT
Abbott said Tuesday it has received U.S. expanded indication for Humira to inhibit joint damage/improve function in psoriatic arthritis.
Abbott's Humira gets expanded indication related news:
- FDA Expands Use of Abbott's Humira — Government/ Industry Regulation News from StratCenter.com
- Abbott's HUMIRA® Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients with Arthritis — Health News from Medical News Today
- Abbott's Humira Positive in 2 Studies — Operations-Related News from StratCenter.com
- Abbott Begins Kos Tender Offer — Financial News News from StratCenter.com
- ACR: Humira Shows 'Profound' Benefit for Kids With Rheumatoid Arthritis — MedPage Today Pediatrics
- Abbott's HUMIRA Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients With Psoriatic Arthritis — Government/ Industry Regulation News from StratCenter.com
- Abbott Labs Commences Tender Offer for All Outstanding Shares of Kos Pharmaceuticals — StratWire - Business of Healthcare NewsFeed
- Expanded playoffs could fix problemsA new system might improve regular season — NewsOk.com - NewsOK News
- Service group expanded to meet customer demand — Other analytical instruments latest news on Laboratorytalk
- APS Healthcare Wins 18 New and Expanded Accounts — RedOrbit News - Health
Latest news from United Press International - Health Business:
- AmerisourceBergen tests Rx tracking plan
- Lilly: Arxxant cuts sight loss in diabetes
- Merck: Arcoxia heart risk same as Voltaren
- Corcept tests psych. major depression Rx
- Neurogen's obesity drug in phase 1 trial
- Analysis: Insurance horizons expanding
- Dendreon seeks OK for Provenge
- Robots caring for stroke patients
- Diabetes drug stalls heart disease
- Diabetes drug also helps arteries